Comparison of the effect of oral captopril with sublingual captopril in lowering blood pressure in patients with acute high blood pressure

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220516054869N2

Enrollment

138

Registered

2022-08-08

Start date

2022-09-23

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute hypertension. Essential (primary) hypertension

Interventions

Intervention 1: Intervention group:Sublingual captopril of Exir pharmaceutical company 25 mg once after entering the study. Intervention 2: Control group: Oral captopril 25 mg of Exir pharmaceutical c

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with systolic blood pressure above 160 or diastolic blood pressure above 100 referred to the FAST (outpatient) emergency department of Khatam Al-Anbia Hospital in 1401

Exclusion criteria

Exclusion criteria: Patients who need blood pressure injection treatment and hospitalization Patients who have used blood pressure pills an hour before the visit Patients who have a history of kidney problems Patients with end organ damage Pregnancy Decreased level of consciousness

Design outcomes

Primary

Measure	Time frame
Decreased blood pressure by more than 10 mm Hg. Timepoint: 30, 10 and 60 minutes. Method of measurement: alpk2 300v mercury pressure gauge.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Abdolrazaghnejad

Zahedan University of Medical Sciences

ali.abdorazzagh@gmail.com+98 54 3322 3003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026